SAN DIEGO, April 16, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that Takeda Pharmaceuticals International GmbH, the Company's partner in the United Kingdom, has accepted the first shipment of Vitaros®, Apricus' novel topical on-demand treatment for erectile dysfunction ("ED").
Help employers find you! Check out all the jobs and post your resume.
